Sirona Biochem Presents New Results From Glycoprotein Program at BIO-Europe

VANCOUVER, BC--(Marketwired - October 26, 2015) - Sirona Biochem Corp. (TSX VENTURE: SBM) (ZSB.F) (the "Company") announces that its Chief Business Development Officer, Attila Hajdu, will be presenting at BIO-Europe on November 4, 2015, at 10:15 am GMT at the International Congress Centre in Munich, Germany.

New results from the glycoprotein program for anti-aging and regenerative medicine will be presented, including positive efficacy data and potential new collaborative projects with cosmetic companies.

The conference is attended by major multinational pharmaceutical corporations and provides further opportunities to engage leading companies in partnering discussions for the newest skin-lightener, SBM-TFC-1067 (1067) and the glycoprotein compounds SBM-TFC-837,1165 and 1287.

"Clearly, we have significantly progressed partnering discussions for 1067 with a select group of companies that have been testing our compound since June, including formulation testing," said Attila Hajdu. "This conference provides an opportunity to broaden the base of companies interested in licensing 1067. We were very excited about the interest from several new companies following Cosmetic 360 in Paris."

Major companies attending the conference include Allergan, GSK, JT Pharma, Pfizer and many others.

BIO-Europe® is the EBD Group's flagship conference, and continues the tradition of providing life science companies with high caliber partnering opportunities. BIO-Europe is organized by EBD Group, the leading partnering firm for the global biotechnology industry, in alliance with the Biotechnology Industry Organization (BIO). For more information please visit the conference website at http://www.ebdgroup.com/bes.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.